Tags:CauseDevelopmentDrugFinanceFinTechHealthManagementProductResearch
Amplyx Antifungal amplex.com Bio/Genomics - Recent Invested 2015, 2017, 2020 Amplyx has a broad spectrum antifungal with IV & oral formulations. The two lead products are fosmanogepix (APX001) for the treatment of life-threatening fungal infections caused by pathogens such as Candida, Aspergillus and rare molds; and MAU868, a monoclonal antibody designed to neutralize the BK virus which can cause significant morbidity and mortality in transplant patients.
Total raised: $160.5M

Investors 6

Funding Rounds 3

DateSeriesAmountInvestorsDeal News
19.05.2020Series C$53M-Amplyx Pha...
02.08.2017Series C$67M-Amplyx Pha...
11.11.2015Series B$40.5M-Amplyx Pha...

Mentions in press and media 15

DateTitleDescriptionCategoryAuthorSource
03.12.2020Amplyx Ann... SAN DIEGO, Dec. 3, 2020 /PRN...--prnewswire...
20.05.2020Amplyx clo...---arixbiosci...
19.05.2020 Amplyx...San Diego-based Amplyx Pharmac...--socaltech....
19.05.2020Amplyx Pha...Amplyx Pharmaceuticals, a San ...USA-finsmes.co...
03.08.2017Term Sheet...MARKDOWNS AGAIN After we wrot...--fortune.co...
02.08.2017Amplyx Pha...-Portfolio ...-sofinnova....
02.08.2017NEA Joins ...Amplyx Pharmaceuticals, a comp...--citybizlis...
02.08.2017Amplyx Pha...Amplyx Pharmaceuticals, a San ...USA-finsmes.co...
02.08.2017 Amplyx...San Diego-based Amplyx Pharmac...--socaltech....
02.08.2017Amplyx Pha...Amplyx Pharmaceuticals Inc., a...--sdbj.com/n...
Show more